Date | Compound | Laboratory | Indication | Type of Information |
---|---|---|---|---|
2015-06-09 | rxRNAori® compounds targeting Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) | RXi Pharmaceuticals (USA - MA) | Granting of a patent | |
2015-10-20 | siRNA sequences targeting vascular endothelial growth factor (VEGF) | RXi Pharmaceuticals (USA - MA) | Granting of a patent | |
2016-04-19 | RXI-109 and other connective tissue growth factor (CTGF) targeting self-delivering RNAi compounds (sd-rxRNA®) | RXi Pharmaceuticals (USA - MA) | fibrotic disorders, including skin fibrosis |
Granting of a patent |
2015-11-19 | fentanyl iontophoretic transdermal system | Incline Therapeutics Europe (UK) The Medicines Company (USA - NJ) | post-operative pain short-term management of acute post-operative pain in adult patients requiring opioid analgesia in the hospital |
Granting of a Market Authorisation in the EU |
2015-12-01 | glycerol phenylbutyrate | Horizon Pharma (Ireland) Horizon Therapeutics (USA - CA) | urea cycle disorders including deficiencies of carbamoyl phosphate-synthase-I, ornithine carbamoyltransferase, argininosuccinate synthetase, argininosuccinate lyase, arginase I and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome who cannot be managed by dietary protein restriction and/or amino acid supplementation alone |
Granting of a Market Authorisation in the EU |
2015-11-16 | dapagliflozin/metformin | AstraZeneca (UK) | type 2 diabetes |
Granting of a Market Authorisation in the EU |
2015-11-09 | dapagliflozin | AstraZeneca (UK) | type 2 diabetes |
Granting of a Market Authorisation in the EU |
2015-10-22 | daptomycin | Novartis (Switzerland) | complicated skin and soft-tissue infections (cSSTI) |
Positive opinion for the granting of a Market Authorisation in the EU |
2015-10-22 | aprepitant | Merck&Co (USA - NJ) | prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in children, toddlers and infants from the age of 6 months to less than 12 years. |
Positive opinion for the granting of a Market Authorisation in the EU |
2016-04-20 | autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor | Kite Pharma (USA - CA) | acute lymphoblastic leukaemia | Granting of the orphan status in the US |
2016-04-20 | autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3 zeta chimeric antigen receptor | Kite Pharma (USA - CA) | chronic lymphocytic leukaemia/small lymphocytic lymphoma | Granting of the orphan status in the US |
2015-11-11 | azacitidine | Celgene (USA - NJ) | nasopharyngeal carcinoma |
Granting of the orphan status in the EU |
2015-11-11 | humanised fusion protein consisting of extracellular domain of CD24 linked to IgG1 Fc domain | Enpharma (UK)/OncoImmune (USA - MI) | prevention of graft-versus-host disease |
Granting of the orphan status in the EU |
2015-11-11 | interferon alfa-n3 | Hemipsherx Biopharma (USA - PA) | Middle East respiratory syndrome |
Granting of the orphan status in the EU |
2015-11-11 | recombinant human interleukin-3 truncated diphtheria toxin fusion protein | Spector Consulting (France) | blastic plasmacytoid dendritic cell neoplasm |
Granting of the orphan status in the EU |
2016-04-14 | (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide | Asphalion (Spain) Debiopharm (Switzerland) | ovarian cancer |
Granting of the orphan status in the US |
2015-11-11 | adeno-associated viral vector serotype 8 encoding the human ATP7B gene under the control of the human alpha-1 antitrypsin promoter | Aligen Therapeutics (Spain) | Wilson disease | Granting of the orphan status in the EU |
2015-11-11 | adenovirus associated viral vector serotype 5 containing the human RPE65 gene | Athena Vision (UK) | Leber’s congenital amaurosis | Granting of the orphan status in the EU |
2015-11-11 | adenovirus associated viral vector serotype 8 containing the human CNGB3 gene | Alan Boyd Consultants (UK) | achromatopsia caused by mutations in the CNGA3 gene |
Granting of the orphan status in the EU |
2018-10-05 | autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3 zeta chimeric antigen receptor | Kite Pharma, a Gilead company (USA - CA) |
|
Granting of a Market Authorisation in the EU |
© 2024 Biopharmanalyses - Powered by Samacom+